Cellular Immunotherapy

Mechanism

Related News

BriaCell Transfers Soluble CD80 License to BriaPro; Four Posters Accepted at AACR 2026

Mar 10, 2026

BriaCell Therapeutics announced an asset purchase agreement transferring its Soluble CD80 license to majority-owned subsidiary BriaPro, while four abstracts were accepted for presentation at the 2026 AACR Annual Meeting.

Next-Generation CAR-T and CAR-NK Cell Therapies Show Promise in Cancer Treatment

Feb 25, 2026

Recent advances in chimeric antigen receptor cell therapies highlight improved designs for CAR-T and CAR-NK treatments, with new strategies addressing efficacy and safety challenges in both hematologic and solid tumors.